glp 1 receptor agonist weight loss A clinician's perspective 📝 GLP-1 agonists are primarily approved for type 2 diabetes, management, and cardiovascular risk reduction, but are increasingly used off-label in dermatology where metabolic dysfunction plays a Type:Ebook + Audiobook Bundle New oral GLP-1 drug energy-support

glp 1 receptor agonist weight loss A clinician's perspective 📝 GLP-1 agonists are primarily approved for type 2 diabetes, management, and cardiovascular risk reduction, but are increasingly used off-label in dermatology where metabolic dysfunction plays a Type:Ebook + Audiobook Bundle New oral GLP-1 drug energy-support

New oral GLP-1 drug delivers up to 12% weight loss in 36 weeks

New Formulations: Efforts are underway to create more convenient formulations, including longer-acting injectables that may only require monthly administration and improved oral versions

energy-support

Type:Ebook + Audiobook Bundle

September 2025: Pfizer announced its agreement to acquire Metsera in a deal valued at up to USD 7.3 billion, strengthening its pipeline of next-generation GLP-1, amylin, and obesity therapies